{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"73.4","value":"7844"},{"groupId":"OG001","spread":"91.8","value":"10374"},{"groupId":"OG002","spread":"37.1","value":"9690"},{"groupId":"OG003","spread":"64.0","value":"11817"},{"groupId":"OG004","spread":"29.2","value":"12706"},{"groupId":"OG005","spread":"22.6","value":"11245"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"title":"AUCt"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"79.0","value":"6392"},{"groupId":"OG001","spread":"85.9","value":"8944"},{"groupId":"OG002","spread":"37.7","value":"8365"},{"groupId":"OG003","spread":"66.3","value":"10932"},{"groupId":"OG004","spread":"27.4","value":"11167"},{"groupId":"OG005","spread":"20.7","value":"9768"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"title":"AUC24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"85.4","value":"8867"},{"groupId":"OG001","spread":"99.8","value":"11992"},{"groupId":"OG002","spread":"38.4","value":"10087"},{"groupId":"OG003","spread":"72.1","value":"14361"},{"groupId":"OG004","spread":"29.2","value":"14242"},{"groupId":"OG005","spread":"28.5","value":"12424"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"5"}],"units":"Participants"}],"title":"AUCinf"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"description":"Measurements include: AUC from time zero to the last measurable concentration (AUCt), AUC from time zero to 24 hours (AUC24), and AUC from time zero to infinity (AUCinf).","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"nab-paclitaxel 120 mg/m\\^2 intravenously (IV) on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the recommended phase 2 dose (RP2D).","id":"OG000","title":"Phase 1: Nab-Paclitaxel 120 mg/m^2"},{"description":"nab-paclitaxel 150 mg/m\\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.","id":"OG001","title":"Phase 1: Nab-Paclitaxel 150 mg/m^2"},{"description":"nab-paclitaxel 180 mg/m\\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.","id":"OG002","title":"Phase 1: Nab-Paclitaxel 180 mg/m^2"},{"description":"nab-paclitaxel 210 mg/m\\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.","id":"OG003","title":"Phase 1: Nab-Paclitaxel 210 mg/m^2"},{"description":"nab-paclitaxel 240 mg/m\\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.","id":"OG004","title":"Phase 1: Nab-Paclitaxel 240 mg/m^2"},{"description":"nab-paclitaxel 270 mg/m\\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.","id":"OG005","title":"Phase 1: Nab-Paclitaxel 270 mg/m^2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK population: all participants who received at least one dose of nab-paclitaxel and had evaluable concentration data for given measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants <6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)","title":"Phase 1: Area Under the Plasma Concentration-Time Curve (AUC)","type":"SECONDARY","unitOfMeasure":"ng*h/mL"}